

## P&T Motion History Antiemetics

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate update	Reiteration of prior motion	Decision
aprepitant/fosaprepitant dolasetron <b>doxylamine /pyridoxine</b> granisetron <ul style="list-style-type: none"> <li>• oral tablet</li> <li>• IV solution</li> <li>• <b>Sancuso (transdermal patch)</b></li> <li>• <b>Sustol (SQ prefilled syringe)</b></li> </ul> <b>netupitant/palonosetron</b> ondansetron <ul style="list-style-type: none"> <li>• IV solution</li> <li>• oral solution</li> <li>• ODT</li> <li>• oral tablet</li> <li>• <b>Zuplenz (oral film)</b></li> </ul> palonosetron <b>rolapitant</b>	<p>After considering the evidence of safety, efficacy and special populations I move that aprepitant, doxylamine /pyridoxine, netupitant/palonosetron, fosaprepitant, granisetron, ondansetron, rolapitant, dolasetron, and palonosetron are efficacious for their FDA approved indications. The preferred drug list must include at least one medication that includes alternate routes approved in both adults and children. The antiemetics can be subject to therapeutic interchange within their mechanism of action in the Washington preferred drug list. The preferred drug list must include a neuro kinin 1 antagonist for patients receiving highly emetogenic chemotherapy and radiation therapy.</p> <p>Motion: Flatebo 2<sup>nd</sup>: Brown</p>	June 21, 2017	Yes Figueroa Sanderson	No	Passed unanimous

**BOLD** = now eligible this expanded scan

\*new drug identified in scan not eligible for inclusion on PDL.